Leg discomfort is easy to misclassify. A patient may describe calf fatigue as aging, hip pain, arthritis, or a side effect of being less active. Yet in the right clinical context, those symptoms may be an early signal of peripheral artery disease, or PAD. Knowing when should clinicians order ABI testing helps practices move from symptom management alone toward a more complete vascular assessment.

The ankle-brachial index, or ABI, is a noninvasive comparison of systolic blood pressure at the ankle and arm. It can help identify lower-extremity arterial obstruction, support PAD diagnosis, establish a baseline, and guide next clinical steps. It is not a screening test for every adult at every visit. Its value is greatest when a patient's symptoms, examination findings, or risk profile create a reasonable concern for vascular disease.

When Should Clinicians Order ABI? Start With Clinical Suspicion

A resting ABI should be considered when the history or physical examination suggests PAD. Classic intermittent claudication remains a clear reason to test: reproducible muscle discomfort, cramping, heaviness, or fatigue in the calf, thigh, or buttock that occurs with walking and improves with rest. In practice, however, many patients do not present with that textbook pattern.

Patients may instead report that they have begun avoiding walks, cannot keep up with family members, or develop leg weakness after a predictable distance. Some have atypical exertional symptoms, including burning, aching, numbness, or generalized fatigue. Diabetes, neuropathy, arthritis, spinal disease, and chronic pain can all obscure the symptom pattern. An ABI can provide useful objective information when the clinical picture is uncertain.

Examination findings can also justify testing. Diminished or absent pedal pulses, a femoral bruit, cool skin, delayed capillary refill, nonhealing wounds, ischemic skin changes, or asymmetric lower-extremity findings should prompt consideration of a vascular assessment. A patient with a foot ulcer should not be assumed to have a purely neuropathic or pressure-related problem until perfusion has been considered.

Clinicians should also act promptly when symptoms raise concern for limb-threatening ischemia. Rest pain in the forefoot, tissue loss, gangrene, or a wound that is not healing warrants timely vascular evaluation and, when indicated, referral. Sudden pain, pallor, pulselessness, paresthesia, paralysis, or a cold limb may indicate acute limb ischemia. That is an urgent clinical scenario, not a routine outpatient ABI decision.

Risk Profiles That Make ABI Testing More Valuable

PAD is often clinically silent until functional limitation or tissue compromise develops. For that reason, ABI testing may be reasonable for patients at increased risk even when they do not report classic claudication. Current cardiovascular guidance generally identifies older adults, people with diabetes, tobacco exposure, chronic kidney disease, dyslipidemia, hypertension, and known atherosclerotic disease as populations in whom vascular risk deserves closer attention.

The threshold for ordering an ABI should be lower for a patient with diabetes who has reduced protective sensation, a history of ulceration, or new foot changes. Diabetes can accelerate atherosclerosis while neuropathy reduces the pain signals that might otherwise bring PAD to attention. Similarly, patients with chronic kidney disease may have both elevated vascular risk and arterial calcification that affects ABI interpretation.

Known coronary artery disease, carotid disease, abdominal aortic aneurysm, or prior stroke or transient ischemic attack should also sharpen the clinician's index of suspicion. Atherosclerosis is a systemic process. Identifying lower-extremity disease can strengthen risk-reduction conversations around tobacco cessation, lipid management, blood pressure control, glycemic management, exercise, antiplatelet therapy when appropriate, and foot protection.

At the same time, broad testing without a clinical rationale can create inefficiency and confusing follow-up. ABI is not generally recommended as a routine test for low-risk, asymptomatic adults. A documented indication, thoughtful patient selection, and an established plan for abnormal results make the service more clinically meaningful.

Symptoms That Deserve a Closer Vascular Look

A useful clinical question is not simply whether a patient has leg pain. It is whether the symptom behavior could reflect impaired arterial flow. Symptoms that recur with a similar level of exertion and improve after a short period of rest are particularly suggestive. So are complaints of a foot that feels colder than the other, reduced walking tolerance, slow-healing sores, or nighttime foot pain relieved by dangling the leg.

PAD can coexist with lumbar stenosis, osteoarthritis, venous disease, and neuropathy. Neurogenic claudication may improve with spinal flexion rather than rest alone. Venous discomfort may worsen with prolonged standing and improve with elevation. Neuropathic pain may burn or tingle at rest and may not correlate reliably with exertion. These distinctions help, but they are not always clean in a busy practice. Objective testing can help clarify whether arterial disease is contributing to the patient's limitation.

For podiatry, endocrinology, primary care, pain medicine, and wound-focused settings, this distinction has practical consequences. A patient may need more than a change in analgesic therapy or footwear if circulation is compromised. Earlier recognition can support appropriate referral before a minor lesion becomes a complex wound.

Interpret ABI Results in Context

ABI is calculated by dividing the ankle systolic pressure by the brachial systolic pressure. In general, an ABI from 1.00 to 1.40 is considered normal. A value of 0.91 to 0.99 is borderline, while 0.90 or lower is abnormal and supports a PAD diagnosis in the appropriate clinical setting. Lower values generally indicate more significant arterial obstruction, but the result must always be interpreted alongside symptoms, pulses, wound status, and the full patient history.

An ABI greater than 1.40 can be just as clinically meaningful. It may indicate noncompressible, calcified arteries, a finding seen more often in diabetes and chronic kidney disease. In that situation, a toe-brachial index, or TBI, may provide a more reliable assessment because digital arteries are less likely to be noncompressible. Segmental pressures, pulse-volume recordings, duplex imaging, or specialist evaluation may also be appropriate depending on the presentation.

A normal resting ABI does not rule out every vascular explanation for exertional symptoms. When a patient has a compelling claudication history but a normal or borderline resting result, exercise ABI testing can help uncover flow limitation that is not apparent at rest. This is where clinical judgment matters most: a single number should inform care, not replace it.

Build ABI Into a Practical Care Pathway

For healthcare organizations, successful ABI testing is less about adding another isolated service and more about creating a consistent pathway. Staff should know which patient histories and findings trigger testing, how results are reviewed, which abnormalities require same-day escalation, and how follow-up is documented. Clear protocols help preserve clinical quality while reducing variability between providers.

The workflow should also account for patients whose vascular risk overlaps with neuropathy, autonomic dysfunction, or cardiovascular disease. Fragmented testing can mean multiple appointments, incomplete assessments, and missed opportunities to connect symptoms across systems. A more integrated approach can help providers identify patterns earlier while keeping the visit manageable for patients and staff.

US MedResources VitalScan supports this model with an FDA 510(k)-cleared, noninvasive platform that combines vascular assessment, including ABI, PAD, pulse-wave, and toe-brachial index evaluation, with autonomic, sudomotor/neuropathy, and ECG-related assessments. Trained staff can complete testing in approximately 15 minutes, with immediate interpretive reporting to support clinical decision-making. For practices managing complex chronic disease populations, this can create a more efficient route to a broader risk discussion without significantly disrupting existing operations.

A documented ABI workflow may also create opportunities for appropriately reimbursable diagnostic services when medical necessity, supervision, documentation, coding, and payer requirements are met. Coverage and payment policies vary by payer and setting, so organizations should validate their own requirements rather than treating reimbursement as automatic. The lasting value comes from using the information to improve care decisions, patient education, follow-up, and referral coordination.

Use the Result to Move Care Forward

An abnormal ABI should lead to action appropriate to the patient's symptoms and severity. That may include cardiovascular risk optimization, structured exercise counseling, foot-care education, medication review, vascular imaging, or referral to a vascular specialist. A borderline or normal result may still warrant further evaluation when symptoms remain concerning. For patients with diabetes or noncompressible vessels, TBI and perfusion-focused testing may be more informative than repeating a standard ABI alone.

The most useful question is not whether every patient needs an ABI. It is whether a patient with exertional symptoms, abnormal pulses, a chronic wound, or meaningful atherosclerotic risk is leaving the visit without the vascular insight needed to guide the next decision. When that answer is yes, timely ABI testing can turn a vague complaint into a clearer, more actionable care plan.